wyeth
levine
argued
november
decided
march
petitioner
wyeth
manufactures
antinausea
drug
phenergan
clinician
injected
respondent
levine
phenergan
method
whereby
drug
injected
directly
patient
vein
drug
entered
levine
artery
developed
gangrene
doctors
amputated
forearm
levine
brought
damages
action
alleging
inter
alia
wyeth
failed
provide
adequate
warning
significant
risks
administering
phenergan
method
vermont
jury
determined
levine
injury
occurred
phenergan
label
included
adequate
warning
awarded
damages
pain
suffering
substantial
medical
expenses
loss
livelihood
professional
musician
declining
overturn
verdict
trial
rejected
wyeth
argument
levine
claims
federal
law
phenergan
labeling
approved
federal
food
drug
administration
fda
vermont
affirmed
held
federal
law
levine
claim
phenergan
label
contain
adequate
warning
method
administration
pp
argument
levine
claims
impossible
wyeth
comply
duties
underlying
claims
federal
labeling
duties
rejected
although
manufacturer
generally
may
change
drug
label
fda
approves
supplemental
application
agency
changes
effected
cbe
regulation
permits
certain
preapproval
labeling
changes
add
strengthen
warning
improve
drug
safety
pursuant
cbe
regulation
wyeth
unilaterally
added
stronger
warning
administration
evidence
fda
ultimately
rejected
labeling
change
wyeth
cramped
reading
cbe
regulation
broad
assertion
unilaterally
changing
phenergan
label
violated
federal
law
governing
unauthorized
distribution
misbranding
drugs
based
fundamental
misunderstanding
fda
rather
manufacturer
bears
primary
responsibility
drug
labeling
central
premise
food
drug
cosmetic
act
fdca
fda
regulations
manufacturer
bears
responsibility
content
label
times
pp
wyeth
argument
requiring
comply
duty
provide
stronger
warning
interfere
congress
purpose
entrusting
expert
agency
drug
labeling
decisions
meritless
relies
untenable
interpretation
congressional
intent
overbroad
view
agency
power
state
law
history
fdca
shows
congress
intend
actions
advancing
argument
fda
must
presumed
established
specific
labeling
standard
leaves
room
different
judgments
wyeth
relies
statement
congress
preamble
fda
regulation
declaring
claims
threaten
fda
statutorily
prescribed
role
although
agency
regulation
force
law
conflicting
state
requirements
case
involves
regulation
merely
agency
assertion
state
law
obstacle
achieving
statutory
objectives
congress
authorized
federal
agency
state
law
directly
weight
accords
agency
explanation
state
law
impact
federal
scheme
depends
thoroughness
consistency
persuasiveness
skidmore
swift
standard
fda
preamble
merit
deference
inherently
suspect
light
fda
failure
offer
interested
parties
notice
opportunity
comment
question
odds
available
evidence
congress
purposes
reverses
fda
longstanding
position
state
law
complementary
form
drug
regulation
without
providing
reasoned
explanation
geier
american
honda
motor
distinguished
pp
affirmed
stevens
delivered
opinion
kennedy
souter
ginsburg
breyer
joined
breyer
filed
concurring
opinion
thomas
filed
opinion
concurring
judgment
alito
filed
dissenting
opinion
roberts
scalia
joined
wyeth
petitioner
diana
levine
writ
certiorari
vermont
march
justice
stevens
delivered
opinion
directly
injecting
drug
phenergan
patient
vein
creates
significant
risk
catastrophic
consequences
vermont
jury
found
petitioner
wyeth
manufacturer
drug
failed
provide
adequate
warning
risk
awarded
damages
respondent
diana
levine
compensate
amputation
arm
warnings
phenergan
label
deemed
sufficient
federal
food
drug
administration
fda
approved
wyeth
new
drug
application
later
approved
changes
drug
labeling
question
must
decide
whether
fda
approvals
provide
wyeth
complete
defense
levine
tort
claims
conclude
phenergan
wyeth
brand
name
promethazine
hydrochloride
antihistamine
used
treat
nausea
injectable
form
phenergan
administered
intramuscularly
intravenously
administered
intravenously
either
method
whereby
drug
injected
directly
patient
vein
method
whereby
drug
introduced
saline
solution
hanging
intravenous
bag
slowly
descends
catheter
inserted
patient
vein
drug
corrosive
causes
irreversible
gangrene
enters
patient
artery
levine
injury
resulted
injection
phenergan
april
previous
visits
local
clinic
treatment
migraine
headache
received
intramuscular
injection
demerol
headache
phenergan
nausea
combination
provide
relief
returned
later
day
received
second
injection
drugs
time
physician
assistant
administered
drugs
method
phenergan
entered
levine
artery
either
needle
penetrated
artery
directly
drug
escaped
vein
surrounding
tissue
phenomenon
called
perivascular
extravasation
came
contact
arterial
blood
result
levine
developed
gangrene
doctors
amputated
first
right
hand
entire
forearm
addition
pain
suffering
levine
incurred
substantial
medical
expenses
loss
livelihood
professional
musician
settling
claims
health
center
clinician
levine
brought
action
damages
wyeth
relying
negligence
theories
although
phenergan
labeling
warned
danger
gangrene
amputation
following
inadvertent
levine
alleged
labeling
defective
failed
instruct
clinicians
use
method
intravenous
administration
instead
higher
risk
method
broadly
alleged
phenergan
reasonably
safe
intravenous
administration
foreseeable
risks
gangrene
loss
limb
great
relation
drug
therapeutic
benefits
app
wyeth
filed
motion
summary
judgment
arguing
levine
claims
federal
law
found
merit
either
wyeth
field
argument
since
abandoned
conflict
argument
respect
contention
actual
conflict
specific
fda
order
levine
action
reviewed
sparse
correspondence
wyeth
fda
phenergan
labeling
found
evidence
wyeth
earnestly
attempted
strengthen
injection
warning
fda
specifically
disallowed
stronger
language
record
developed
lack
ed
evidence
fda
set
ceiling
matter
ibid
evidence
presented
jury
trial
showed
risk
injection
perivascular
extravasation
almost
entirely
eliminated
use
rather
administration
iv
drip
started
saline
flow
properly
catheter
vein
fluid
entering
artery
surrounding
tissue
see
contrast
even
careful
experienced
clinician
using
method
occasionally
expose
artery
phenergan
see
phenergan
labeling
warned
injection
perivascular
extravasation
advised
hen
administering
irritant
drug
intravenously
usually
preferable
inject
tubing
intravenous
infusion
set
known
functioning
satisfactorily
labeling
contain
specific
warning
risks
administration
trial
record
also
contains
correspondence
wyeth
fda
discussing
phenergan
label
fda
first
approved
injectable
phenergan
wyeth
submitted
supplemental
new
drug
applications
agency
approved
proposing
labeling
changes
wyeth
submitted
third
supplemental
application
response
new
fda
rule
governing
drug
labels
next
years
wyeth
fda
intermittently
corresponded
phenergan
label
notable
activity
occurred
fda
suggested
different
warnings
risk
arterial
exposure
wyeth
submitted
revised
labeling
incorporating
proposed
changes
fda
respond
instead
requested
wyeth
labeling
use
without
addressing
wyeth
submission
instructed
etain
verbiage
current
label
regarding
injection
changes
labeling
related
injection
fda
approved
wyeth
application
instructing
phenergan
final
printed
label
must
identical
approved
package
insert
based
regulatory
history
trial
judge
instructed
jury
consider
evidence
wyeth
compliance
fda
requirements
compliance
establish
warnings
adequate
also
instructed
without
objection
wyeth
fda
regulations
permit
drug
manufacturer
change
product
label
add
strengthen
warning
product
without
prior
fda
approval
long
later
submits
revised
warning
review
approval
answering
questions
special
verdict
form
jury
found
wyeth
negligent
phenergan
defective
product
result
inadequate
warnings
instructions
intervening
cause
broken
causal
connection
product
defects
plaintiff
injury
awarded
total
damages
reduced
account
levine
earlier
settlement
health
center
clinician
august
trial
filed
comprehensive
opinion
denying
wyeth
motion
judgment
matter
law
making
findings
fact
based
trial
record
supplemented
one
letter
wyeth
found
trial
rejected
wyeth
arguments
determined
direct
conflict
fda
regulations
levine
claims
regulations
permit
strengthened
warnings
without
fda
approval
interim
basis
record
contained
evidence
least
reports
amputations
similar
levine
since
also
found
state
tort
liability
case
obstruct
fda
work
agency
paid
passing
attention
question
whether
warn
administration
phenergan
addition
noted
state
law
serves
compensatory
function
distinct
federal
regulation
vermont
affirmed
held
jury
verdict
conflict
fda
labeling
requirements
phenergan
wyeth
warned
administration
without
prior
fda
approval
federal
labeling
requirements
create
floor
ceiling
state
regulation
dissent
chief
justice
reiber
argued
jury
verdict
conflicted
federal
law
inconsistent
fda
conclusion
intravenous
administration
phenergan
safe
effective
importance
issue
coupled
fact
fda
changed
position
state
tort
law
endorses
views
expressed
chief
justice
reiber
dissent
persuaded
us
grant
wyeth
petition
certiorari
question
presented
petition
whether
fda
drug
labeling
judgments
preempt
state
law
product
liability
claims
premised
theory
different
labeling
judgments
necessary
make
drugs
reasonably
safe
use
pet
cert
ii
wyeth
makes
two
separate
arguments
first
impossible
comply
duty
modify
phenergan
labeling
without
violating
federal
law
see
fidelity
fed
sav
loan
assn
de
la
cuesta
second
recognition
levine
state
tort
action
creates
unacceptable
obstacle
accomplishment
execution
full
purposes
objectives
congress
hines
davidowitz
substitutes
lay
jury
decision
drug
labeling
expert
judgment
fda
preface
evaluation
arguments
identify
two
factual
propositions
decided
trial
proceedings
emphasize
two
legal
principles
guide
analysis
review
history
controlling
federal
statute
trial
proceedings
established
levine
injury
occurred
phenergan
label
included
adequate
warning
risks
method
administering
drug
record
contains
evidence
physician
assistant
administered
greater
dose
label
prescribed
may
inadvertently
injected
drug
artery
rather
vein
continued
inject
drug
levine
complained
pain
nevertheless
jury
rejected
wyeth
argument
clinician
conduct
intervening
cause
absolved
liability
see
app
jury
verdict
finding
wyeth
negligent
well
strictly
liable
jury
also
determined
levine
injury
foreseeable
inadequate
label
proximate
cause
levine
injury
supported
record
longer
challenged
trial
proceedings
established
critical
defect
phenergan
label
lack
adequate
warning
risks
administration
levine
also
offered
evidence
method
contraindicated
phenergan
never
administered
intravenously
even
method
perhaps
reason
dissent
incorrectly
assumes
duty
issue
duty
contraindicate
method
see
post
vermont
explained
jury
verdict
established
phenergan
warning
insufficient
mandate
particular
replacement
warning
require
contraindicating
administration
may
number
ways
wyeth
strengthen
phenergan
warning
without
completely
eliminating
administration
therefore
need
decide
whether
state
rule
proscribing
intravenous
administration
narrower
question
presented
whether
federal
law
levine
claim
phenergan
label
contain
adequate
warning
using
method
administration
answer
question
must
guided
two
cornerstones
jurisprudence
first
purpose
congress
ultimate
touchstone
every
case
medtronic
lohr
internal
quotation
marks
omitted
see
retail
clerks
schermerhorn
second
cases
particularly
congress
field
traditionally
occupied
assumption
historic
police
powers
superseded
federal
act
unless
clear
manifest
purpose
congress
lohr
quoting
rice
santa
fe
elevator
order
identify
purpose
congress
appropriate
briefly
review
history
federal
regulation
drugs
drug
labeling
congress
enacted
first
significant
public
health
law
federal
food
drugs
act
ch
stat
act
prohibited
manufacture
interstate
shipment
adulterated
misbranded
drugs
supplemented
protection
consumers
already
provided
state
regulation
liability
congress
became
increasingly
concerned
unsafe
drugs
fraudulent
marketing
enacted
federal
food
drug
cosmetic
act
fdca
ch
stat
amended
et
seq
act
substantial
innovation
provision
premarket
approval
new
drugs
required
every
manufacturer
submit
new
drug
application
including
reports
investigations
specimens
proposed
labeling
fda
review
application
became
effective
manufacturer
prohibited
distributing
drug
fda
reject
application
determined
drug
safe
use
labeled
though
agency
failed
act
application
became
effective
days
filing
fdca
stat
congress
amended
fdca
shifted
burden
proof
fda
manufacturer
agency
prove
harm
keep
drug
market
amendments
required
manufacturer
demonstrate
drug
safe
use
conditions
prescribed
recommended
suggested
proposed
labeling
distribute
drug
stat
addition
amendments
required
manufacturer
prove
drug
effectiveness
introducing
substantial
evidence
drug
effect
purports
represented
conditions
use
prescribed
recommended
suggested
proposed
labeling
enlarged
fda
powers
protect
public
health
assure
safety
effectiveness
reliability
drugs
congress
took
care
preserve
state
law
amendments
added
saving
clause
indicating
provision
state
law
invalidated
upon
direct
positive
conflict
fdca
consistent
provision
state
suits
continued
unabated
despite
fda
regulation
riegel
medtronic
slip
ginsburg
dissenting
see
collecting
state
cases
congress
enacted
express
provision
medical
devices
see
stat
codified
declined
enact
provision
prescription
drugs
levine
injury
lawsuit
congress
amended
fdca
stat
first
time
granted
fda
statutory
authority
require
manufacturer
change
drug
label
based
safety
information
becomes
available
drug
initial
approval
however
congress
enact
provision
senate
bill
required
fda
preapprove
changes
drug
labels
see
pp
passed
proposing
new
instead
adopted
rule
construction
make
clear
manufacturers
remain
responsible
updating
labels
see
stat
iii
wyeth
first
argues
levine
claims
impossible
comply
duties
underlying
claims
federal
labeling
duties
see
de
la
cuesta
fda
premarket
approval
new
drug
application
includes
approval
exact
text
proposed
label
see
cfr
generally
speaking
manufacturer
may
change
drug
label
fda
approves
supplemental
application
however
fda
regulation
permits
manufacturer
make
certain
changes
label
receiving
agency
approval
among
things
changes
effected
cbe
regulation
provides
manufacturer
changing
label
add
strengthen
contraindication
warning
precaution
adverse
reaction
add
strengthen
instruction
dosage
administration
intended
increase
safe
use
drug
product
may
make
labeling
change
upon
filing
supplemental
application
fda
need
wait
fda
approval
iii
wyeth
argues
cbe
regulation
implicated
case
amendment
provides
manufacturer
may
change
label
reflect
newly
acquired
information
fed
reg
resting
language
wyeth
argues
simply
reaffirmed
interpretation
regulation
effect
case
tried
wyeth
contends
changed
phenergan
label
response
new
information
fda
considered
maintains
levine
pointed
information
concerning
risks
administration
thus
wyeth
insists
impossible
discharge
obligation
provide
stronger
warning
administration
without
violating
federal
law
wyeth
argument
misapprehends
federal
drug
regulatory
scheme
burden
establishing
defense
need
decide
whether
cbe
regulation
consistent
fdca
previous
version
regulation
wyeth
urge
wyeth
revised
phenergan
label
even
accordance
amended
regulation
fda
explained
notice
final
rule
acquired
limited
new
data
also
encompasses
new
analyses
previously
submitted
data
rule
accounts
fact
risk
information
accumulates
time
data
may
take
different
meaning
light
subsequent
developments
sponsor
submits
adverse
event
information
fda
later
conducts
new
analysis
data
showing
risks
different
type
greater
severity
frequency
reports
previously
submitted
fda
sponsor
meets
requirement
acquired
information
see
also
record
limited
concerning
newly
acquired
information
wyeth
risks
administration
phenergan
wyeth
argue
trial
information
required
cbe
labeling
change
levine
however
present
evidence
least
incidents
prior
injury
phenergan
injection
resulted
gangrene
amputation
see
app
first
incident
came
wyeth
attention
notified
fda
worked
agency
change
phenergan
label
later
years
amputations
continued
occur
wyeth
analyzed
accumulating
data
added
stronger
warning
administration
drug
wyeth
argues
unilaterally
added
warning
violated
federal
law
governing
unauthorized
distribution
misbranding
argument
change
phenergan
labeling
subjected
liability
unauthorized
distribution
rests
assumption
labeling
change
rendered
phenergan
new
drug
lacking
effective
application
strengthening
warning
administration
made
phenergan
new
drug
see
defining
new
drug
cfr
warning
rendered
phenergan
misbranded
fdca
provide
drug
misbranded
simply
manufacturer
altered
label
instead
misbranding
provision
focuses
substance
label
among
things
proscribes
labels
fail
include
adequate
warnings
moreover
statute
contemplates
federal
juries
resolve
misbranding
claims
fda
belief
drug
misbranded
conclusive
see
idea
fda
bring
enforcement
action
manufacturer
strengthening
warning
pursuant
cbe
regulation
difficult
accept
neither
wyeth
identified
case
fda
done
wyeth
cramped
reading
cbe
regulation
broad
reading
fdca
misbranding
unauthorized
distribution
provisions
premised
fundamental
misunderstanding
wyeth
suggests
fda
rather
manufacturer
bears
primary
responsibility
drug
labeling
yet
many
amendments
fdca
fda
regulations
remained
central
premise
federal
drug
regulation
manufacturer
bears
responsibility
content
label
times
charged
crafting
adequate
label
ensuring
warnings
remain
adequate
long
drug
market
see
cfr
requiring
manufacturer
revise
label
include
warning
soon
reasonable
evidence
association
serious
hazard
drug
placing
responsibility
postmarketing
surveillance
manufacturer
fed
reg
manufacturers
continue
responsibility
federal
law
maintain
labeling
update
labeling
new
safety
information
indeed
prior
fda
lacked
authority
order
manufacturers
revise
labels
see
stat
congress
granted
fda
authority
reaffirmed
manufacturer
obligations
referred
specifically
cbe
regulation
reflects
manufacturer
ultimate
responsibility
label
provides
mechanism
adding
safety
information
label
prior
fda
approval
see
stating
manufacturer
retains
responsibility
maintain
label
accordance
existing
requirements
including
subpart
part
sections
title
code
federal
regulations
successor
regulations
emphasis
added
thus
risk
gangrene
injection
phenergan
became
apparent
wyeth
duty
provide
warning
adequately
described
risk
cbe
regulation
permitted
provide
warning
receiving
fda
approval
course
fda
retains
authority
reject
labeling
changes
made
pursuant
cbe
regulation
review
manufacturer
supplemental
application
retains
authority
reviewing
supplemental
applications
absent
clear
evidence
fda
approved
change
phenergan
label
conclude
impossible
wyeth
comply
federal
state
requirements
wyeth
offered
evidence
argue
attempted
give
kind
warning
required
vermont
jury
prohibited
see
tr
oral
arg
see
also
brief
amicus
curiae
suggest
fda
intended
prohibit
strengthening
warning
administration
agency
deemed
warning
inappropriate
reviewing
phenergan
drug
applications
trial
vermont
rejected
account
matter
fact
decision
wyeth
motion
judgment
matter
law
trial
found
evidence
record
either
fda
manufacturer
gave
passing
attention
issue
versus
administration
app
vermont
likewise
concluded
fda
made
affirmative
decision
preserve
method
intended
prohibit
wyeth
strengthening
warning
administration
moreover
wyeth
argue
supplied
fda
evaluation
analysis
concerning
specific
dangers
posed
method
accordingly
credit
wyeth
contention
fda
prevented
adding
stronger
warning
method
intravenous
impossibility
demanding
defense
record
us
wyeth
failed
demonstrate
impossible
comply
federal
state
requirements
cbe
regulation
permitted
wyeth
unilaterally
strengthen
warning
mere
fact
fda
approved
phenergan
label
establish
prohibited
change
iv
wyeth
also
argues
requiring
comply
duty
provide
stronger
warning
administration
obstruct
purposes
objectives
federal
drug
labeling
regulation
levine
tort
claims
maintains
interfere
congress
purpose
entrust
expert
agency
make
drug
labeling
decisions
strike
balance
competing
objectives
brief
petitioner
find
merit
argument
relies
untenable
interpretation
congressional
intent
overbroad
view
agency
power
state
law
wyeth
contends
fdca
establishes
floor
ceiling
drug
regulation
fda
approved
drug
label
verdict
may
deem
label
inadequate
regardless
whether
evidence
fda
considered
stronger
warning
issue
glaring
problem
argument
evidence
congress
purposes
contrary
building
act
congress
enacted
fdca
bolster
consumer
protection
harmful
products
see
kordel
sullivan
congress
provide
federal
remedy
consumers
harmed
unsafe
ineffective
drugs
statute
subsequent
amendment
evidently
determined
widely
available
state
rights
action
provided
appropriate
relief
injured
may
also
recognized
remedies
consumer
protection
motivating
manufacturers
produce
safe
effective
drugs
give
adequate
warnings
congress
thought
suits
posed
obstacle
objectives
surely
enacted
express
provision
point
fdca
history
despite
enactment
express
provision
medical
devices
see
stat
codified
congress
enacted
provision
prescription
drugs
see
riegel
slip
congress
applied
clause
entire
fdca
instead
wrote
clause
applies
medical
devices
silence
issue
coupled
certain
awareness
prevalence
state
tort
litigation
powerful
evidence
congress
intend
fda
oversight
exclusive
means
ensuring
drug
safety
effectiveness
justice
explained
opinion
unanimous
case
federal
particularly
weak
congress
indicated
awareness
operation
state
law
field
federal
interest
nonetheless
decided
stand
concepts
tolerate
whatever
tension
bonito
boats
thunder
craft
boats
internal
quotation
marks
omitted
see
also
supra
discussing
presumption
despite
evidence
congress
regard
state
tort
litigation
obstacle
achieving
purposes
wyeth
nonetheless
maintains
fdca
requires
fda
determine
drug
safe
effective
conditions
set
forth
labeling
agency
must
presumed
performed
precise
balancing
risks
benefits
established
specific
labeling
standard
leaves
room
different
judgments
advancing
argument
wyeth
relies
statement
congress
instead
preamble
fda
regulation
governing
content
format
prescription
drug
labels
see
brief
petitioner
citing
fed
reg
preamble
fda
declared
fdca
establishes
fda
approval
labeling
preempts
conflicting
contrary
state
law
stated
certain
actions
involving
claims
threaten
fda
statutorily
prescribed
role
expert
federal
agency
responsible
evaluating
regulating
drugs
recognized
agency
regulation
force
law
conflicting
state
requirements
see
geier
american
honda
motor
hillsborough
county
automated
medical
laboratories
cases
performed
conflict
determination
relying
substance
state
federal
law
agency
proclamations
faced
regulation
case
rather
agency
mere
assertion
state
law
obstacle
achieving
statutory
objectives
congress
authorized
fda
state
law
directly
cf
authorizing
fda
determine
scope
medical
devices
amendments
clause
question
weight
accord
fda
opinion
prior
cases
given
weight
agency
views
impact
tort
law
federal
objectives
subject
matter
technica
relevant
history
background
complex
extensive
geier
even
cases
however
deferred
agency
conclusion
state
law
rather
attended
agency
explanation
state
law
affects
regulatory
scheme
agencies
special
authority
pronounce
absent
delegation
congress
unique
understanding
statutes
administer
attendant
ability
make
informed
determinations
state
requirements
may
pose
obstacle
accomplishment
execution
full
purposes
objectives
congress
hines
see
geier
lohr
weight
accord
agency
explanation
state
law
impact
federal
scheme
depends
thoroughness
consistency
persuasiveness
cf
mead
skidmore
swift
standard
fda
preamble
merit
deference
fda
issued
notice
proposed
rulemaking
december
explained
rule
contain
policies
federalism
implications
preempt
state
law
fed
reg
see
also
noting
proposed
rule
propose
preempt
state
law
agency
finalized
rule
without
offering
interested
parties
notice
opportunity
comment
articulated
sweeping
position
fdca
effect
regulatory
preamble
agency
views
state
law
inherently
suspect
light
procedural
failure
preamble
odds
evidence
congress
purposes
reverses
fda
longstanding
position
without
providing
reasoned
explanation
including
discussion
state
law
interfered
fda
regulation
drug
labeling
decades
coexistence
fda
position
plainly
reflect
agency
view
times
relevant
litigation
prior
levine
injury
fda
suggest
state
tort
law
stood
obstacle
statutory
mission
contrary
cast
federal
labeling
standards
floor
upon
build
repeatedly
disclaimed
attempt
claims
instance
fda
stated
believe
evolution
state
tort
law
cause
development
standards
odds
agency
regulations
noted
establishing
minimal
standards
drug
labels
intend
preclude
imposing
additional
labeling
requirements
keeping
congress
decision
tort
suits
appears
fda
traditionally
regarded
state
law
complementary
form
drug
regulation
fda
limited
resources
monitor
drugs
manufacturers
superior
access
information
drugs
especially
postmarketing
phase
new
risks
emerge
state
tort
suits
uncover
unknown
drug
hazards
provide
incentives
drug
manufacturers
disclose
safety
risks
promptly
also
serve
distinct
compensatory
function
may
motivate
injured
persons
come
forward
information
actions
particular
lend
force
fdca
premise
manufacturers
fda
bear
primary
responsibility
drug
labeling
times
thus
fda
long
maintained
state
law
offers
additional
important
layer
consumer
protection
complements
fda
agency
preamble
represents
dramatic
change
position
largely
based
fda
new
position
wyeth
argues
case
presents
conflict
state
federal
law
analogous
one
issue
geier
held
state
tort
claims
premised
honda
failure
install
airbags
conflicted
federal
regulation
require
airbags
cars
department
transportation
dot
promulgated
rule
provided
car
manufacturers
range
choices
among
passive
restraint
devices
geier
rejecting
standard
agency
called
gradual
mix
passive
restraints
order
spur
technological
development
win
consumer
acceptance
plaintiff
claim
car
manufacturers
duty
install
airbags
presented
obstacle
achieving
variety
mix
devices
federal
regulation
sought
wyeth
dissent
contend
regulatory
scheme
case
nearly
identical
described
quite
different
geier
dot
conducted
formal
rulemaking
adopted
plan
phase
mix
passive
restraint
devices
examining
rule
dot
contemporaneous
record
revealed
factors
agency
weighed
balance
struck
determined
state
tort
suits
presented
obstacle
federal
scheme
conducting
analysis
considered
agency
explanation
state
law
interfered
regulation
regarding
support
independent
conclusion
plaintiff
tort
claim
obstructed
federal
regime
contrast
occasion
case
consider
effect
specific
agency
regulation
bearing
force
law
fda
newfound
opinion
expressed
preamble
state
law
frustrate
agency
implementation
statutory
mandate
fed
reg
merit
deference
reasons
indeed
complex
extensive
regulatory
history
background
relevant
case
geier
undercut
fda
recent
pronouncements
reveal
longstanding
coexistence
state
federal
law
fda
traditional
recognition
remedies
recognition
place
time
agency
reviewed
wyeth
phenergan
short
wyeth
persuaded
us
claims
like
levine
obstruct
federal
regulation
drug
labeling
congress
repeatedly
declined
state
law
fda
recently
adopted
position
state
tort
suits
interfere
statutory
mandate
entitled
weight
although
recognize
claims
might
well
frustrate
achievement
congressional
objectives
case
conclude
impossible
wyeth
comply
state
federal
law
obligations
levine
claims
stand
obstacle
accomplishment
congress
purposes
fdca
accordingly
judgment
vermont
affirmed
ordered
wyeth
petitioner
diana
levine
writ
certiorari
vermont
march
justice
breyer
concurring
write
separately
emphasize
statement
occasion
case
consider
effect
specific
agency
regulation
bearing
force
law
ante
state
tort
law
sometimes
help
food
drug
administration
fda
uncover
unknown
drug
hazards
encourage
drug
manufacturers
disclose
safety
risks
ante
also
possible
state
tort
law
sometimes
interfere
fda
desire
create
drug
label
containing
specific
set
cautions
instructions
also
note
argued
state
tort
law
sometimes
raise
prices
point
sick
unable
obtain
drugs
need
see
lasagna
chilling
effect
product
liability
new
drug
development
liability
maze
huber
litan
eds
fda
may
seek
determine
whether
state
tort
law
acts
help
hindrance
achieving
safe
medical
care
congress
sought
medtronic
lohr
breyer
concurring
part
concurring
judgment
cf
bates
dow
agrosciences
llc
breyer
concurring
may
seek
embody
determinations
lawful
specific
regulations
describing
example
labeling
requirements
serve
ceiling
well
floor
possible
determinations
effect
see
lohr
supra
opinion
breyer
citing
hillsborough
county
automated
medical
laboratories
agree
however
regulation
issue
case
wyeth
petitioner
diana
levine
writ
certiorari
vermont
march
justice
thomas
concurring
judgment
agree
fact
food
drug
administration
fda
approved
label
petitioner
wyeth
drug
phenergan
judgment
judgment
based
jury
finding
label
adequately
warn
risk
involved
administering
phenergan
injection
method
federal
law
without
prior
approval
fda
wyeth
add
ed
strengthen
ed
information
label
contraindication
warning
precaution
adverse
reaction
cfr
iii
dosage
administration
intended
increase
safe
use
drug
product
iii
order
reflect
newly
acquired
information
including
new
analyses
previously
submitted
data
dangers
administration
phenergan
fed
reg
thus
possible
wyeth
label
market
phenergan
compliance
federal
law
also
providing
additional
warning
information
label
beyond
previously
approved
fda
addition
federal
law
give
drug
manufacturers
unconditional
right
market
federally
approved
drug
times
precise
label
initially
approved
fda
vermont
judgment
case
therefore
directly
conflict
federal
law
write
separately
however
join
majority
implicit
endorsement
implied
doctrines
particular
become
increasingly
skeptical
purposes
objectives
jurisprudence
approach
routinely
invalidates
state
laws
based
perceived
conflicts
broad
federal
policy
objectives
legislative
history
generalized
notions
congressional
purposes
embodied
within
text
federal
law
implied
doctrines
wander
far
statutory
text
inconsistent
constitution
concur
judgment
order
ensure
protection
fundamental
liberties
atascadero
state
hospital
scanlon
internal
quotation
marks
omitted
constitution
establishes
system
dual
sovereignty
federal
government
gregory
ashcroft
framers
adopted
mandated
balance
power
atascadero
state
hospital
supra
reduce
risk
tyranny
abuse
either
front
federalist
structure
joint
sovereigns
preserves
people
numerous
advantages
decentralized
government
sensitive
diverse
needs
heterogeneous
society
increase
opportunity
citizen
involvement
democratic
processes
gregory
supra
furthermore
framers
observed
compound
republic
america
provides
double
security
rights
people
power
surrendered
people
first
divided
two
distinct
governments
portion
allotted
subdivided
among
distinct
separate
departments
federalist
beloff
ed
federalist
system
possess
sovereignty
concurrent
federal
government
subject
limitations
imposed
supremacy
clause
tafflin
levitt
way
supremacy
clause
gives
federal
government
decided
advantage
delicate
balance
federal
state
sovereigns
gregory
long
acting
within
powers
granted
constitution
congress
may
impose
ibid
extraordinary
power
federalist
system
ibid
nonetheless
retain
substantial
sovereign
authority
amdt
powers
delegated
constitution
prohibited
reserved
respectively
people
see
also
alden
maine
printz
new
york
gregory
supra
tafflin
supra
accordance
text
structure
constitution
powers
delegated
proposed
constitution
federal
government
defined
hose
remain
state
governments
numerous
indefinite
federalist
indeed
protecting
constitutional
government
preservation
maintenance
governments
much
within
design
care
constitution
preservation
union
maintenance
national
government
texas
white
wall
quoted
new
york
supra
result
order
protect
delicate
balance
power
mandated
constitution
supremacy
clause
must
operate
accordance
terms
clause
provides
constitution
laws
shall
made
pursuance
thereof
treaties
made
shall
made
authority
shall
law
land
judges
every
state
shall
bound
thereby
thing
constitution
laws
state
contrary
notwithstanding
art
vi
cl
respect
federal
laws
supremacy
clause
gives
status
made
pursuance
constitution
ibid
see
story
commentaries
constitution
hereinafter
story
observed
supremacy
laws
attached
made
pursuance
constitution
federal
laws
made
pursuance
constitution
must
comply
two
key
structural
limitations
constitution
ensure
federal
government
amass
much
power
expense
first
structural
limitation
parties
raised
case
constitution
conferral
upon
congress
governmental
powers
discrete
enumerated
ones
printz
supra
see
also
morrison
new
york
supra
mcculloch
maryland
wheat
government
acknowledged
one
enumerated
powers
second
structural
limitation
complex
set
procedures
congress
president
must
follow
enact
laws
see
ins
chadha
setting
forth
constitution
bicameral
presentment
clauses
art
cls
prescribe
define
respective
functions
congress
executive
legislative
process
framers
acutely
conscious
bicameral
requirement
presentment
clauses
serve
essential
constitutional
functions
chadha
allowing
passage
legislation
proceeded
deliberate
deliberative
process
finely
wrought
exhaustively
considered
framers
supremacy
clause
thus
requires
effect
given
federal
standards
policies
set
forth
necessarily
follow
statutory
text
produced
constitutionally
required
bicameral
presentment
procedures
see
story
actions
federal
government
pursuant
constitutional
powers
invasions
residuary
authorities
smaller
societies
law
land
merely
acts
usurpation
deserve
treated
light
constitutional
principles
become
increasing
ly
reluctan
expand
federal
statutes
beyond
terms
doctrines
implied
bates
dow
agrosciences
llc
thomas
concurring
judgment
part
dissenting
part
review
broad
implied
precedents
particularly
purposes
objectives
jurisprudence
increased
concerns
implied
doctrines
always
constitutionally
applied
vague
potentially
boundless
doctrine
purposes
objectives
geier
american
honda
motor
stevens
dissenting
example
state
law
based
interpretation
broad
federal
policy
objectives
legislative
history
generalized
notions
congressional
purposes
contained
within
text
federal
law
see
pharmaceutical
research
mfrs
america
walsh
thomas
concurring
judgment
referring
concomitant
danger
invoking
obstacle
based
arbitrary
selection
one
purpose
exclusion
others
crosby
national
foreign
trade
council
scalia
concurring
judgment
criticizing
majority
reliance
legislative
history
discern
statutory
intent
intent
perfectly
obvious
face
th
statute
geier
supra
relying
regulatory
history
agency
comments
government
litigating
position
determine
federal
law
state
law
congressional
agency
musings
however
satisfy
art
requirements
enactment
federal
law
therefore
state
law
supremacy
clause
analyzing
effect
federal
statutes
regulations
validly
promulgated
thereunder
vidence
purpose
must
sought
text
structure
provision
issue
comply
constitution
csx
easterwood
see
also
new
york
ferc
federal
agency
may
state
law
acting
within
scope
congressional
delegated
authority
agency
literally
power
act
let
alone
validly
enacted
legislation
sovereign
state
unless
congress
confers
power
upon
internal
quotation
marks
omitted
second
alteration
original
camps
town
harrison
thomas
dissenting
noting
treating
unenacted
congressional
intent
law
constitutionally
dubious
analysis
freewheeling
judicial
inquiry
whether
state
statute
tension
federal
objectives
inquiry
whether
ordinary
meanings
state
federal
law
conflict
bates
supra
thomas
concurring
judgment
part
dissenting
part
internal
quotation
marks
citation
omitted
see
also
geier
supra
dissenting
analysis
least
matter
precise
statutory
regulatory
construction
rather
exercise
judicial
policymaking
internal
quotation
marks
omitted
must
turn
whether
state
law
conflicts
text
relevant
federal
statute
federal
regulations
authorized
text
see
foster
love
finding
conflict
question
turn
ed
entirely
meaning
state
federal
statutes
issue
see
also
new
york
ferc
supra
ii
determined
two
categories
conflict
wyeth
contends
issue
case
first
found
compliance
federal
state
regulations
physical
impossibility
one
engaged
interstate
commerce
florida
lime
avocado
growers
paul
second
determined
federal
law
state
law
circumstances
particular
case
state
law
stands
obstacle
accomplishment
execution
full
purposes
objectives
congress
hines
davidowitz
wyeth
first
contends
impossible
comply
duty
modify
phenergan
labeling
without
violating
federal
law
ante
opinion
stevens
majority
explains
text
relevant
federal
statutory
provisions
corresponding
regulations
directly
conflict
judgment
us
used
different
formulations
standard
used
deciding
whether
state
federal
law
conflict
thus
lead
impossibility
doctrine
see
geier
supra
case
state
law
penalizes
federal
law
requires
american
telephone
telegraph
central
office
telephone
claims
directly
conflict
federal
law
cited
geier
supra
describing
cas
involving
impossibility
florida
lime
avocado
growers
supra
compliance
federal
state
regulations
physical
impossibility
generally
articulated
narrow
impossibility
standard
see
crosby
citing
florida
lime
avocado
growers
supra
see
also
sprietsma
mercury
marine
locke
part
overly
broad
sweep
purposes
objectives
approach
see
infra
rendered
unnecessary
rely
impossibility
fact
explained
narrow
physical
impossibility
standard
best
proxy
determining
state
federal
laws
directly
conflict
purposes
supremacy
clause
instances
physically
impossible
comply
state
federal
law
even
state
federal
laws
give
directly
conflicting
commands
see
nelson
preemption
rev
example
federal
law
gives
individual
right
engage
certain
behavior
state
law
prohibits
laws
give
contradictory
commands
notwithstanding
fact
individual
comply
electing
refrain
covered
behavior
ibid
therefore
physical
impossibility
may
appropriate
standard
determining
whether
text
state
federal
laws
directly
conflict
see
ibid
concluding
supremacy
clause
limit
direct
conflicts
cases
physically
impossible
conflicts
arguing
evidence
founding
supports
standard
see
also
supra
requiring
claims
directly
conflict
federal
law
story
suggesting
instead
state
law
supremacy
clause
repugnant
constitution
emphasis
added
nonetheless
whatever
precise
constitutional
contours
implied
may
satisfied
operate
respondent
judgment
text
federal
laws
issue
require
judgment
issue
either
narrow
physical
impossibility
standard
florida
lime
avocado
growers
supra
general
direc
conflict
standard
supra
fda
changes
effected
regulation
cfr
iii
promulgated
pursuant
fda
statutory
authority
physically
possible
wyeth
market
phenergan
compliance
federal
vermont
law
majority
explains
wyeth
changed
warning
label
regarding
without
violating
federal
law
see
ante
changes
effected
regulation
allows
drug
manufacturers
change
labels
without
fda
preapproval
changes
add
strengthen
contraindication
warning
precaution
adverse
reaction
iii
add
strengthen
instruction
dosage
administration
intended
increase
safe
use
drug
product
iii
order
reflect
newly
acquired
information
including
new
analyses
previously
submitted
data
fed
reg
terms
regulations
learning
new
incidences
amputation
resulting
administration
phenergan
see
ante
federal
law
gave
wyeth
authority
change
phenergan
label
strengthen
warning
strengthen
precaution
iii
strengthen
instruction
administration
method
increase
safe
use
drug
product
iii
thus
physically
possible
wyeth
comply
requirement
provide
stronger
warnings
phenergan
risks
administration
method
continuing
market
phenergan
compliance
federal
law
addition
text
statutory
provisions
governing
fda
drug
labeling
regulations
promulgated
thereunder
give
drug
manufacturers
unconditional
right
market
federally
approved
drug
times
precise
label
initially
approved
fda
thus
direct
conflict
federal
labeling
law
judgment
statute
prohibits
interstate
marketing
drug
except
federally
approved
see
person
shall
introduce
deliver
introduction
interstate
commerce
new
drug
unless
approval
application
filed
pursuant
subsection
section
effective
respect
drug
emphasis
added
say
statute
wyeth
may
market
drug
without
federal
approval
without
label
say
federal
approval
gives
wyeth
unfettered
right
time
market
drug
specific
label
federally
approved
initial
approval
label
amounts
finding
fda
label
safe
purposes
gaining
federal
approval
market
drug
represent
finding
drug
labeled
never
deemed
unsafe
later
federal
action
case
application
state
law
instead
fda
regulations
require
drug
manufacturer
initial
federal
approval
drug
label
revise
federally
approved
label
include
warning
soon
reasonable
evidence
association
serious
hazard
drug
cfr
drug
manufacturers
also
required
establish
maintain
records
make
reports
fda
ny
adverse
event
associated
use
drug
humans
whether
considered
drug
related
received
federal
approval
addition
manufacturer
must
make
periodic
reports
adverse
drug
experience
associated
drug
include
history
actions
taken
since
last
report
adverse
drug
experiences
example
labeling
changes
studies
initiated
ii
records
reports
made
fda
withdraw
approval
drug
see
also
secretary
may
withdraw
approval
application
secretary
finds
applicant
failed
establish
system
maintaining
required
records
repeatedly
deliberately
failed
maintain
records
make
required
reports
fda
may
also
determine
drug
longer
safe
use
based
clinical
experience
tests
scientific
data
ibid
approval
may
withdrawn
secretary
finds
clinical
experience
tests
scientific
data
show
drug
unsafe
use
conditions
use
upon
basis
application
approved
text
statutory
provisions
accompanying
regulatory
scheme
governing
fda
drug
approval
process
therefore
establish
fda
initial
approval
drug
guarantee
drug
label
never
need
changed
nothing
text
statutory
regulatory
scheme
necessarily
insulates
wyeth
liability
state
law
simply
fda
approved
particular
label
sum
relevant
federal
law
give
wyeth
right
judgment
took
away
possible
wyeth
comply
federal
law
judgment
issue
federal
statute
regulations
neither
prohibited
stronger
warning
label
required
state
judgment
insulated
wyeth
risk
liability
direct
conflict
federal
state
law
judgment
cf
finding
federal
law
forbade
common
carriers
extending
communications
privileges
requested
claims
foster
finding
federal
statute
required
congressional
elections
particular
date
different
provided
state
statute
wyeth
also
contends
state
federal
law
conflict
recognition
state
tort
action
creates
unacceptable
accomplishment
execution
full
purposes
objectives
congress
hines
davidowitz
substitutes
lay
jury
decision
drug
labeling
expert
judgment
fda
ante
entire
body
purposes
objectives
jurisprudence
inherently
flawed
cases
improperly
rely
legislative
history
broad
atextual
notions
congressional
purpose
even
congressional
inaction
order
state
law
see
supra
therefore
join
majority
analysis
claim
see
ante
reaffirmation
purposes
objectives
jurisprudence
ante
analyzing
congressional
purposes
ante
quoting
standard
hines
davidowitz
geier
ante
nn
analyzing
case
light
geier
first
formulated
current
purposes
objectives
standard
hines
considered
whether
federal
alien
registration
act
alien
registration
act
adopted
commonwealth
pennsylvania
find
two
statutes
terms
directly
conflicted
see
hines
supra
citing
stat
tit
purdon
supp
citing
act
june
stat
analyzing
numerous
extratextual
sources
finding
without
concluding
terms
federal
state
laws
directly
conflict
see
also
noting
conceded
federal
act
operation
point
conflict
state
statute
stone
dissenting
nonetheless
determined
confined
considering
merely
terms
relevant
federal
law
conducting
analysis
rather
went
ask
whether
state
law
stands
obstacle
accomplishment
execution
full
purposes
objectives
congress
looked
far
beyond
relevant
federal
statutory
text
instead
embarked
freeranging
speculation
purposes
federal
law
must
see
addition
meaning
relevant
federal
text
attempted
discern
nature
power
exerted
congress
object
sought
attained
character
obligations
imposed
law
looked
part
public
sentiment
noting
pposition
laws
singling
aliens
particularly
dangerous
undesirable
groups
country
ibid
also
relied
statements
particular
members
congress
congressional
inaction
finding
pertinent
numerous
bills
requirements
similar
pennsylvania
law
failed
garner
enough
votes
congress
become
law
nn
concluding
sources
revealed
federal
purpose
protect
personal
liberties
aliens
one
uniform
national
registration
system
held
pennsylvania
law
justice
stone
dissent
questioned
majority
decision
read
exclusive
registration
system
aliens
statute
specifically
provide
exclusivity
see
noted
concern
state
power
improperly
diminished
doctrine
driven
conceptions
policy
congress
ha
expressed
plainly
inferred
legislation
ha
enacted
ibid
view
nothing
congress
enacted
denie
practicable
means
identifying
alien
residents
recording
whereabouts
yet
hines
majority
employed
override
numerous
state
laws
even
though
enacted
federal
law
point
conflict
ed
state
legislation
harmonious
consequences
broad
approach
purposes
objectives
exemplified
decision
geier
majority
dissent
incorporate
analysis
today
see
ante
nn
post
opinion
alito
geier
pursuant
national
traffic
motor
vehicle
safety
act
safety
act
stat
et
seq
ed
department
transportation
dot
promulgated
federal
motor
vehicle
safety
standard
required
auto
manufacturers
equip
vehicles
passive
restraints
case
required
decide
whether
safety
act
state
tort
action
plaintiff
claimed
auto
manufacturer
though
compliance
federal
standard
nonetheless
equipped
automobile
airbags
first
concluded
safety
act
express
provision
saving
clause
read
together
expressly
state
claims
see
proceeded
consider
whether
state
action
nonetheless
obstacle
purposes
federal
law
held
state
tort
claim
relying
large
part
comments
dot
made
promulgating
regulation
statements
government
made
brief
regulatory
history
related
federal
regulation
passive
restraints
see
particular
majority
found
dot
intended
deliberately
provid
manufacturer
range
choices
among
different
passive
restraint
devices
bring
mix
different
devices
introduced
gradually
time
based
comments
dot
made
promulgating
regulation
rather
safety
act
text
majority
also
embarked
judicial
inquiry
dot
sought
objectives
considering
regulatory
history
government
brief
described
dot
safety
standard
ying
secretary
policy
judgment
safety
best
promoted
manufacturers
installed
alternative
protection
systems
fleets
rather
one
particular
system
every
car
quoting
brief
amicus
curiae
geier
american
honda
motor
see
also
based
ex
post
administrative
litigating
position
inferences
regulatory
history
final
commentary
dissenting
found
state
action
required
manufacturers
cars
similar
plaintiff
injured
install
airbags
rather
passive
restraint
systems
therefore
presented
obstacle
variety
mix
devices
federal
regulation
sought
phase
gradually
decision
geier
apply
purposes
objectives
based
agency
comments
regulatory
history
agency
litigating
positions
especially
flawed
given
conflicted
plain
statutory
text
saving
clause
within
safety
act
explicitly
preserved
state
actions
providing
ompliance
federal
motor
vehicle
safety
standard
issued
subchapter
exempt
person
liability
common
law
ed
see
engine
mfrs
assn
south
coast
air
quality
management
statutory
construction
must
begin
language
employed
congress
assumption
ordinary
meaning
language
accurately
expresses
legislative
purpose
internal
quotation
marks
omitted
west
virginia
univ
hospitals
casey
best
evidence
th
purpose
statute
statutory
text
adopted
houses
congress
submitted
president
addition
reliance
divined
purpose
federal
law
gradually
phase
mix
passive
restraint
systems
order
invalidate
state
imposition
greater
safety
standard
contrary
general
express
statutory
goal
safety
act
reduce
traffic
accidents
deaths
injuries
persons
resulting
traffic
accidents
repeatedly
stated
statutory
language
plain
must
enforced
according
terms
see
jimenez
quarterman
see
also
dodd
lamie
trustee
hartford
underwriters
ins
union
planters
bank
text
geier
directly
addressed
precise
question
issue
end
matter
well
agency
must
give
effect
unambiguously
expressed
intent
congress
national
assn
home
builders
defenders
wildlife
slip
internal
quotation
marks
omitted
text
allowed
state
actions
like
one
issue
geier
authority
comb
agency
commentaries
find
basis
alternative
conclusion
applying
purposes
objectives
geier
case
allowed
vacate
judgment
issued
another
sovereign
based
nothing
assumptions
goals
untethered
constitutionally
enacted
federal
law
authorizing
federal
regulatory
standard
see
watters
wachovia
bank
stevens
dissenting
noting
affects
allocation
powers
among
sovereigns
agency
literally
power
act
let
alone
law
sovereign
state
unless
congress
confers
power
upon
new
york
ferc
quoting
louisiana
pub
serv
fcc
thus
agency
individual
member
congress
state
judgment
merely
musing
goals
intentions
found
within
authorized
statutory
text
see
supra
purposes
objectives
jurisprudence
also
problematic
encourages
overly
expansive
reading
statutory
text
desire
divine
broader
purposes
statute
inevitably
leads
assume
congress
wanted
pursue
policies
costs
even
text
reflects
different
balance
see
geier
supra
stevens
dissenting
finding
evidence
support
notion
dot
secretary
intended
advance
purposes
safety
standard
costs
nelson
repeatedly
noted
frustrates
rather
effectuates
legislative
intent
simplistically
assume
whatever
furthers
statute
primary
objective
must
law
norfolk
southern
sorrell
quoting
rodriguez
per
curiam
federal
legislation
often
result
compromise
legislators
groups
marked
divergent
interests
see
ragsdale
wolverine
world
wide
thus
statute
text
might
reflect
compromise
parties
wanted
pursue
particular
goal
different
extents
see
ibid
noting
family
medical
leave
act
provision
workweeks
yearly
leave
result
compromise
must
given
effect
courts
silkwood
finding
state
law
though
allegedly
frustrated
primary
purpose
atomic
energy
act
act
provided
purpose
furthered
extent
consistent
health
safety
quoting
ed
see
also
manning
divides
textualists
purposivists
colum
rev
legislators
may
compromise
statute
fully
address
perceived
mischief
accepting
half
loaf
facilitate
law
enactment
therefore
factual
basis
assumption
underlying
purposes
objectives
jurisprudence
every
policy
seemingly
consistent
federal
statutory
text
necessarily
authorized
congress
warrants
effect
instead
federal
system
general
supremacy
clause
particular
accords
effect
policies
actually
authorized
effectuated
statutory
text
majority
reaching
right
conclusion
case
demonstrates
application
purposes
objectives
requires
inquiry
matters
beyond
scope
proper
judicial
review
example
majority
relies
heavily
congress
failure
history
federal
food
drug
cosmetic
act
enact
express
provision
addresses
approval
drug
label
fda
ante
silence
issue
coupled
congress
certain
awareness
prevalence
state
tort
litigation
majority
reasons
evidence
congress
intend
federal
approval
drug
labels
state
tort
judgments
ibid
see
also
ante
construing
inaction
congress
vidently
determined
widely
available
state
rights
action
provided
appropriate
relief
certainly
absence
statutory
provision
state
tort
suits
related
approved
federal
drug
labels
pertinent
finding
lawsuits
relevance
fact
statute
explicitly
lawsuits
inferences
may
draw
congressional
silence
motivations
policies
underlying
congress
failure
act
see
brown
gardner
ongressional
silence
lacks
persuasive
significance
internal
quotation
marks
omitted
myers
fdic
atters
left
unaddressed
comprehensive
detailed
federal
scheme
presumably
left
subject
disposition
provided
state
law
camps
newfound
ur
jurisprudence
explicitly
rejects
notion
mere
congressional
silence
particular
issue
may
read
state
law
case
majority
concluded
silence
congress
believed
state
lawsuits
pose
obstacle
federal
objectives
see
ante
required
conclusion
compelled
text
relevant
statutory
regulatory
provisions
judicial
suppositions
congress
unstated
goals
fact
reaches
proper
conclusion
justify
speculation
reasons
congressional
inaction
case
relied
perceived
congressional
policies
underlying
inaction
find
state
law
shows
willingness
guess
intent
underlying
congressional
inaction
easily
rely
perceptions
regarding
congressional
inaction
give
unduly
broad
effect
federal
law
see
american
ins
assn
garamendi
finding
congress
failure
pass
legislation
indicating
disagreed
president
executive
agreement
supported
least
part
determination
agreement
state
law
either
approach
illegitimate
supremacy
clause
state
law
federal
law
made
pursuance
constitution
art
vi
cl
extratextual
considerations
purposes
underlying
congressional
inaction
see
hoffman
connecticut
dept
income
maintenance
plurality
opinion
finding
policy
arguments
based
text
statute
helpful
tva
hill
individual
appraisal
wisdom
unwisdom
particular
course
consciously
selected
congress
put
aside
process
interpreting
statute
role
merely
interpret
language
statute
enacted
congress
barnhart
sigmon
coal
iii
origins
purposes
objectives
jurisprudence
hines
broad
application
cases
like
geier
illustrate
brand
jurisprudence
facilitates
freewheeling
extratextual
broad
evaluations
purposes
objectives
embodied
within
federal
law
turn
leads
decisions
giving
improperly
broad
effect
judicially
manufactured
policies
rather
statutory
text
enacted
congress
pursuant
constitution
agency
actions
authorized
thereby
sweeping
approach
leads
illegitimate
thus
unconstitutional
invalidation
state
laws
longer
assent
doctrine
state
laws
merely
stan
obstacle
accomplishment
execution
full
purposes
objectives
federal
law
hines
perceived
therefore
respectfully
concur
judgment
wyeth
petitioner
diana
levine
writ
certiorari
vermont
march
justice
alito
chief
justice
justice
scalia
join
dissenting
case
illustrates
tragic
facts
make
bad
law
holds
state
tort
jury
rather
food
drug
administration
fda
ultimately
responsible
regulating
warning
labels
prescription
drugs
result
reconciled
geier
american
honda
motor
general
principles
conflict
respectfully
dissent
frames
question
presented
narro
one
namely
whether
wyeth
duty
provide
adequate
warning
using
method
administer
phenergan
ante
ignores
antecedent
question
fda
jury
vermont
authority
responsibility
determining
adequacy
phenergan
warnings
moreover
unclear
stronger
warning
helped
respondent
see
ante
physician
assistant
treated
disregarded
least
six
separate
warnings
already
phenergan
labeling
respondent
hard
pressed
prove
seventh
made
point
question
presented
case
narrow
one
concern
whether
phenergan
label
bear
stronger
warning
rather
real
issue
whether
state
tort
jury
countermand
fda
considered
judgment
phenergan
warning
label
renders
intravenous
iv
use
safe
indeed
respondent
amended
complaint
alleged
phenergan
reasonably
safe
intravenous
administration
app
respondent
attorney
told
jury
phenergan
label
say
use
drug
intravenously
respondent
expert
told
jury
think
drug
labeled
iv
use
closing
argument
respondent
attorney
told
jury
thank
god
rely
fda
make
safe
ty
decision
make
decision
fda
make
decision
federal
law
however
rely
fda
make
safety
determinations
like
one
made
fda
long
known
risks
associated
iv
push
general
use
administer
phenergan
particular
whether
wisely
fda
concluded
course
extensive
regulatory
proceedings
drug
safe
effective
used
accordance
labeling
unfortunate
fact
respondent
healthcare
providers
ignored
phenergan
labeling
may
make
ideal
turning
tort
suit
frontal
assault
fda
regulatory
regime
drug
labeling
upsets
meaning
supremacy
clause
conflict
jurisprudence
brief
amicus
curiae
ii
extent
purpose
congress
ultimate
touchstone
every
case
medtronic
lohr
internal
quotation
marks
omitted
congress
made
purpose
plain
authorizing
fda
state
tort
juries
determine
circumstances
drug
safe
process
approving
new
drugs
least
rigorous
premarket
approval
process
medical
devices
riegel
medtronic
slip
ginsburg
dissenting
held
latter
tort
suit
conflicted
fda
determination
medical
device
safe
slip
opinion
federal
food
drug
cosmetic
act
fdca
drug
manufacturer
may
market
new
drug
first
submitting
new
drug
application
nda
fda
receiving
agency
approval
see
nda
must
contain
among
things
labeling
proposed
used
drug
full
reports
investigations
made
show
whether
drug
safe
use
whether
drug
effective
use
discussion
benefits
exceed
risks
drug
conditions
stated
labeling
cfr
viii
fda
approve
nda
agency
finds
among
things
drug
safe
use
conditions
prescribed
recommended
suggested
proposed
labeling
thereof
substantial
evidence
drug
effect
purports
represented
conditions
use
prescribed
recommended
suggested
proposed
labeling
thereof
proposed
labeling
false
misleading
particular
fda
approves
drug
manufacturer
remains
obligation
investigate
report
adverse
events
associated
drug
see
cfr
must
periodically
submit
new
information
may
affect
fda
previous
conclusions
safety
effectiveness
labeling
drug
fda
finds
drug
safe
used
accordance
labeling
agency
shall
withdraw
approval
drug
fda
also
shall
deem
drug
misbranded
dangerous
health
used
dosage
manner
frequency
duration
prescribed
recommended
suggested
labeling
thereof
thus
drug
warning
label
serves
standard
fda
determines
whether
product
safe
effective
fed
reg
labeling
centerpiece
risk
management
communicates
health
care
practitioners
agency
formal
authoritative
conclusions
regarding
conditions
product
used
safely
effectively
fed
reg
fda
underscored
importance
places
drug
labels
promulgating
comprehensive
regulations
spanning
entire
part
code
federal
regulations
see
cfr
pt
seven
subparts
separate
sections
set
forth
drug
manufacturers
labeling
obligations
regulations
fda
must
satisfied
drug
warning
label
contains
among
things
summary
essential
scientific
information
needed
safe
effective
use
drug
including
description
clinically
significant
adverse
reactions
potential
safety
hazards
limitations
use
imposed
steps
taken
occur
neither
fdca
implementing
regulations
suggest
juries
may
fda
labeling
decisions
fda
determines
accordance
statutory
mandate
drug
balance
safe
conflict
cases
prohibit
state
countermanding
determination
see
buckman
plaintiffs
legal
fda
struck
somewhat
delicate
balance
statutory
objectives
determined
petitioner
submitted
valid
application
manufacture
medical
device
state
may
use
common
law
negate
international
paper
ouellette
epa
struck
balance
public
private
interests
carefully
addressed
federal
permitting
regime
water
pollution
state
may
use
nuisance
law
upse
chicago
north
western
transp
kalo
brick
tile
interstate
commerce
commission
struck
balance
competing
interests
permitting
abandonment
railroad
line
state
may
use
statutory
common
law
negate
thus
recognizes
irrelevant
conflict
cases
whether
congress
enacted
express
provision
point
fdca
history
ante
see
also
geier
holding
absence
express
clause
bar
ordinary
working
conflict
principles
rather
ordinary
principles
conflict
turn
solely
whether
state
upset
regulatory
balance
struck
federal
agency
see
also
chicago
north
western
transp
supra
describing
conflict
process
first
ascertaining
construction
federal
state
laws
determining
constitutional
question
whether
actually
conflict
internal
quotation
marks
omitted
faithful
application
conflict
cases
compels
conclusion
fda
effort
regulate
safety
efficacy
phenergan
respondent
tort
suit
indeed
result
follows
directly
conclusion
geier
geier
arose
national
traffic
motor
safety
vehicle
act
directs
secretary
department
transportation
dot
establish
order
motor
vehicle
safety
standards
ed
defined
minimum
standard
motor
vehicle
performance
motor
vehicle
equipment
performance
acting
pursuant
statutory
mandate
secretary
transportation
promulgated
federal
motor
vehicle
safety
standard
required
car
manufacturers
include
passive
restraint
systems
devices
work
automatically
protect
occupants
injury
collision
certain
percentage
cars
built
see
cfr
standard
require
installation
particular
type
passive
restraint
instead
gave
manufacturers
option
install
automatic
seatbelts
airbags
suitable
technology
might
develop
provided
restraint
met
performance
requirements
specified
rule
ibid
alexis
geier
drove
honda
accord
tree
although
wearing
seatbelt
nonetheless
suffered
serious
injuries
sued
honda
state
tort
law
alleging
car
negligently
defectively
designed
lacked
airbag
argued
congress
empowered
secretary
set
minimum
standard
vehicle
safety
also
emphasized
national
traffic
motor
safety
vehicle
act
contains
saving
clause
provides
ompliance
federal
motor
vehicle
safety
standard
issued
subchapter
exempt
person
liability
common
law
notwithstanding
statute
saving
clause
notwithstanding
fact
congress
gave
secretary
authority
set
minimum
safety
standards
held
geier
state
tort
suit
reaching
result
relied
heavily
view
secretary
transportation
expressed
amicus
brief
standard
secretary
policy
judgment
safety
best
promoted
manufacturers
installed
alternative
protection
systems
fleets
rather
one
particular
system
every
car
quoting
brief
amicus
curiae
secretary
determined
menu
alternative
technologies
safe
doctrine
conflict
barred
geier
efforts
deem
federally
approved
alternatives
unsafe
state
tort
law
rationale
applies
phenergan
label
fda
offered
medical
professionals
menu
federally
approved
safe
effective
alternatives
including
iv
push
administering
drug
state
tort
suit
respondent
attempted
deem
iv
push
unsafe
ineffective
sure
federal
law
prohibit
wyeth
contraindicating
iv
push
federal
law
prohibit
honda
installing
airbags
cars
held
may
compel
latter
precluded
compelling
former
see
also
fidelity
fed
sav
loan
assn
de
la
cuesta
conflict
evaporate
agency
regulation
simply
permits
compel
action
forbidden
state
law
anything
finding
even
appropriate
fdca
unlike
national
traffic
motor
safety
vehicle
act
contains
evidence
congress
intended
fda
set
minimum
standards
fdca
contain
saving
see
also
ante
conceding
congress
silence
issue
iii
attempt
evade
geier
applicability
case
commits
factual
legal
errors
first
factual
matter
demonstrably
untrue
fda
failed
consider
strike
balance
specific
costs
benefits
associated
iv
push
second
legal
matter
geier
stand
legal
propositions
espoused
dissenters
specifically
rejected
majority
case
third
drug
labeling
jury
verdict
undermines
broader
jurisprudence
broader
workability
federal
regime
phenergan
warning
label
subject
fda
strict
regulatory
oversight
since
least
last
years
fda
focused
specifically
whether
administration
phenergan
safe
effective
performed
accordance
phenergan
label
agency
ultimate
decision
retain
iv
push
one
means
administering
phenergan
albeit
subject
stringent
warnings
reflected
plain
text
phenergan
label
sometimes
boldfaced
font
letters
record
contains
ample
evidence
fda
specifically
considered
reconsidered
strength
phenergan
warnings
light
new
scientific
medical
data
majority
factual
assertions
contrary
mistaken
fda
focus
iv
push
means
administering
phenergan
dates
back
least
august
year
several
representatives
fda
wyeth
met
discuss
phenergan
warning
label
meeting
fda
specifically
proposed
phenergan
injection
used
record
plaintiff
trial
exh
internal
correspondence
langeland
file
hereinafter
memo
tubex
syringe
system
used
exclusively
iv
push
see
app
fda
official
explained
agency
concerns
arose
lawsuits
involving
iv
push
drug
see
memo
fda
aware
cases
involving
amputation
drug
administered
tubex
together
several
additional
cases
involving
necrosis
rather
contraindicating
phenergan
iv
push
however
agency
wyeth
agreed
need
better
instruction
regarding
problems
intraarterial
injection
next
year
fda
convened
advisory
committee
study
among
things
risks
associated
tubex
system
iv
push
app
conclusion
study
committee
recommended
additional
warning
phenergan
label
see
recommend
eliminating
iv
push
drug
label
altogether
response
committee
recommendations
fda
instructed
wyeth
make
several
changes
strengthen
phenergan
label
including
addition
upper
case
warnings
related
iv
push
see
fda
directed
wyeth
amend
label
include
following
text
used
intravenously
phenergan
given
concentration
greater
rate
exceed
injection
properly
running
intravenous
infusion
may
enhance
possibility
detecting
arterial
placement
first
two
quoted
sentences
refers
specifically
iv
push
respondent
medical
expert
testified
trial
label
recommended
rate
administration
exceed
mg
per
minute
refers
iv
push
opposed
say
bag
dripped
couple
hours
second
two
quoted
sentences
refers
iv
drip
see
emphasizing
running
iv
thing
iv
drip
labeling
order
fda
cited
voluminous
materials
suppor
new
stronger
warnings
related
iv
push
preferability
iv
one
articles
specifically
discussed
relative
advantages
disadvantages
iv
drip
compared
iv
push
well
costs
benefits
administering
phenergan
via
iv
fda
also
cited
published
case
reports
gangrene
caused
injection
fda
instructed
wyeth
amend
phenergan
label
accordance
latest
medical
fda
also
studied
drugs
similar
phenergan
cited
numerous
cautionary
articles
one
urged
agency
consider
contraindicating
drugs
iv
use
support
labeling
order
fda
also
cited
numerous
articles
singled
inner
crook
elbow
known
antecubital
fossa
medical
community
commonly
used
injection
site
see
noting
respondent
injection
pushed
antecubital
space
universally
recognized
area
inadvertent
injections
one
articles
explained
numerous
superficial
positions
ulnar
artery
might
occupy
often
entered
attempted
venipuncture
antecubital
fossa
however
brachial
radial
arteries
might
also
quite
superficial
elbow
region
arterial
variations
arm
especially
cubital
fossa
common
numerous
venipuncture
must
performed
area
higher
index
suspicion
must
maintained
forestall
misdirected
injections
stone
donnelly
accidental
injection
thiopental
anesthesiology
omitted
cited
app
based
research
fda
ordered
wyeth
include
specific
warning
related
use
antecubital
space
iv
respondent
injured
phenergan
label
specifically
addressed
iv
push
several
passages
sometimes
lieu
sometimes
addition
discussed
example
label
warned
risks
injection
associated
aspiration
technique
used
conjunction
iv
label
also
cautioned
use
syringes
rigid
plungers
app
used
administer
drug
via
iv
push
respondent
medical
expert
testified
trial
talking
plungers
rigid
needles
way
push
plunger
testimony
john
matthew
moreover
phenergan
label
devoted
almost
full
page
discussing
tubex
system
see
noted
used
administer
drug
via
iv
push
phenergan
label
clearly
authorized
use
iv
push
also
made
clear
iv
push
delivery
method
last
resort
label
specified
preferred
parenteral
route
administration
deep
intramuscular
injection
intramuscular
injection
ineffective
usually
preferable
inject
phenergan
tubing
intravenous
infusion
set
known
functioning
satisfactorily
ibid
see
also
testimony
respondent
medical
expert
john
matthew
conceding
best
way
determine
iv
set
functioning
satisfactorily
use
iv
drip
finally
whatever
reason
medical
professional
chooses
use
iv
push
notice
inadvertent
injection
result
gangrene
affected
extremity
see
also
circumstances
phenergan
injection
given
injection
due
likelihood
severe
arteriospasm
possibility
resultant
gangrene
phenergan
label
also
directs
medical
practitioners
choose
veins
wisely
using
iv
push
due
close
proximity
arteries
veins
areas
commonly
used
intravenous
injection
extreme
care
exercised
avoid
perivascular
extravasation
inadvertent
injection
reports
compatible
inadvertent
injection
phenergan
injection
usually
conjunction
drugs
intended
intravenous
use
suggest
pain
severe
chemical
irritation
severe
spasm
distal
vessels
resultant
gangrene
requiring
amputation
likely
circumstances
ibid
thus
demonstrably
untrue
phenergan
labeling
contain
specific
warning
risks
administration
ante
whatever
else
might
said
extensive
medical
authorities
case
reports
fda
cited
support
approval
administration
phenergan
said
fda
paid
passing
attention
iv
push
ante
said
fda
failed
weigh
costs
benefits
brief
respondent
part
respondent
dispute
fda
conclusion
iv
push
certain
benefits
trial
medical
practitioners
testified
used
iv
push
order
help
swift
timely
way
showed
hospital
second
time
one
day
complaining
intractable
migraines
terrible
pain
inability
bear
light
sound
sleeplessness
spasms
retching
vomiting
every
possible
alternative
treatment
failed
app
testimony
john
matthew
testimony
physician
assistant
jessica
fisch
rather
disputing
benefits
iv
push
respondent
complains
fda
wyeth
underestimated
costs
hence
provide
sufficient
warnings
regarding
risks
fda
mandated
phenergan
label
read
inadvertent
injection
result
gangrene
affected
extremity
fda
required
wyeth
warn
nder
circumstances
phenergan
injection
given
injection
agency
reasonably
assume
medical
professionals
take
care
inject
phenergan
see
also
fed
reg
noting
drug
warning
label
communicates
health
care
practitioners
agency
formal
authoritative
conclusions
regarding
conditions
product
used
safely
effectively
unfortunately
physician
assistant
treated
respondent
case
disregarded
phenergan
label
pushed
drug
single
spot
arm
likely
cause
inadvertent
injection
noted
fda
approved
phenergan
label
textbook
medical
knowledge
antecubital
fossa
creates
high
risk
inadvertent
injection
given
close
proximity
veins
arteries
see
supra
see
also
lippincott
manual
nursing
practice
ed
noting
nursing
alert
antecubital
fossa
recommended
administering
dangerous
drugs
due
potential
extravasation
according
physician
assistant
injured
respondent
however
never
crossed
mind
antecubital
injection
phenergan
hit
artery
app
see
also
ibid
something
aware
time
oblivious
risks
emphasized
phenergan
warnings
physician
assistant
pushed
double
dose
drug
antecubital
artery
course
robably
three
four
minutes
notwithstanding
respondent
complaints
ing
sensation
subsequently
described
extreme
pains
ever
felt
asked
ignored
phenergan
label
failed
stop
pushing
drug
respondent
complained
burning
pains
physician
assistant
explained
crazy
worr
injection
circumstances
fda
however
think
risks
associated
iv
push
especially
antecubital
space
crazy
phenergan
label
clearly
warns
given
balance
fda
struck
costs
benefits
administering
phenergan
via
iv
push
geier
compels
tort
suits
like
one
upset
balance
contrary
conclusion
requires
turning
yesterday
dissent
today
majority
opinion
first
denies
existence
conflict
case
vermont
merely
countermanded
fda
determination
iv
push
safe
performed
accordance
phenergan
warning
label
concludes
conflict
vermont
mandate
particular
label
replacement
one
jury
nullified
state
stopped
short
altogether
contraindicating
administration
ante
emphasized
geier
dissent
assertions
contrary
degree
state
intrusion
upon
federal
law
irrelevant
supremacy
clause
applies
equal
force
state
tort
law
merely
countermands
federal
safety
determination
state
law
altogether
prohibits
car
manufacturers
selling
cars
without
airbags
compare
stevens
dissenting
indeed
recently
last
term
held
supremacy
clause
tate
tort
law
requires
manufacturer
catheters
safer
hence
less
effective
model
fda
approved
riegel
slip
matter
state
stopped
short
altogether
prohibiting
use
catheters
matter
vermont
stopped
short
altogether
prohibiting
method
administering
phenergan
see
also
lohr
breyer
concurring
part
concurring
judgment
noting
anomalous
result
applied
differently
state
tort
suit
premised
inadequacy
fda
safety
regulations
state
law
specifically
prohibited
design
second
today
distinguishes
geier
fda
articulated
intent
without
offering
interested
parties
notice
opportunity
comment
ante
see
also
ante
geier
specifically
rejected
argument
made
dissenters
case
conflict
appropriate
agency
expresses
intent
rulemaking
compare
insist
specific
expression
agency
intent
made
rulemaking
certain
cases
tolerate
conflicts
agency
therefore
congress
unlikely
intended
dissent
said
apparently
welcomes
result
stevens
dissenting
emphasizing
generally
expect
administrative
regulation
declare
intention
state
law
specificity
expectation
serves
ensure
able
dialog
agencies
regarding
decisions
ex
ante
normal
procedures
administrative
procedure
act
internal
quotation
marks
omitted
indeed
arguably
appropriate
geier
fda
unlike
dot
declared
intent
federal
register
see
fed
reg
yet
majority
dismisses
fda
published
preamble
inherently
suspect
ante
afterthought
entitled
weight
ante
compare
lohr
supra
opinion
breyer
emphasizing
fda
special
understanding
likely
impact
state
federal
requirements
well
understanding
whether
extent
state
requirements
may
interfere
federal
objectives
fda
translate
understandings
particularized
intentions
statements
preambles
interpretive
statements
responses
third
distinguishes
geier
dot
regulation
bear
force
law
whereas
fda
preamble
ante
see
also
ante
irrelevant
fda
preamble
bear
force
law
fda
labeling
decisions
surely
see
well
within
fda
discretion
make
labeling
decisions
administrative
adjudications
rather
rulemaking
proceedings
see
sec
chenery
never
previously
held
analysis
turns
agency
choice
latter
former
moreover
said
geier
outcome
hinged
agency
choice
promulgate
rule
see
ante
geier
relied
dissenters
protestations
materials
secretary
regulation
explain
conflict
state
federal
law
compare
stevens
dissenting
ante
breyer
concurring
fourth
sandwiches
discussion
geier
presumption
ante
heavy
emphasis
longstanding
coexistence
state
federal
law
fda
traditional
recognition
remedies
ante
geier
specifically
rejected
argument
made
dissenters
case
presumption
relevant
conflict
analysis
see
stevens
dissenting
simply
ignores
presumption
rather
invoking
presumption
emphasized
applying
ordinary
longstanding
principles
conflict
principles
sole
question
whether
actual
conflict
state
federal
law
follows
automatically
operation
supremacy
clause
see
also
buckman
etitioner
dealings
fda
prompted
federal
law
subject
matter
petitioner
statements
fda
dictated
federal
law
accordingly
contrast
situations
implicating
concerns
historic
primacy
state
regulation
matters
health
safety
presumption
obtains
case
citation
omitted
finally
geier
went
way
emphasize
yet
dissenters
objections
placed
weight
dot
amicus
brief
explained
agency
regulatory
objectives
effects
state
tort
suits
federal
regulatory
regime
compare
stevens
dissenting
criticizing
majority
uph
olding
regulatory
claim
implied
conflict
based
nothing
ex
post
administrative
litigating
position
inferences
regulatory
history
final
commentary
see
also
lohr
recognizing
fda
uniquely
qualified
explain
whether
state
law
conflicts
fda
objectives
yet
today
fda
explanation
conflict
state
tort
suits
federal
labeling
regime
set
forth
agency
amicus
brief
even
mentioned
opinion
instead
relying
fda
explanation
regulatory
purposes
relies
statement
majority
finds
preferable
see
ante
cf
riegel
slip
noting
agency
earlier
position
dissent
describes
length
finds
preferable
compromised
indeed
deprived
claim
deference
fact
longer
agency
position
citation
omitted
altria
group
good
slip
rejecting
petitioners
reliance
effect
agency
longstanding
policy
inconsistent
agency
current
one
justice
breyer
suggests
state
tort
suits
may
help
fda
ante
concurring
opinion
notwithstanding
fda
insistence
state
tort
suits
disrupt
agency
balancing
health
risks
benefits
brief
amicus
curiae
geier
countenance
use
state
tort
suits
fda
labeling
decisions
contrary
conclusion
potentially
consequences
nature
juries
perform
fda
function
explained
riegel
juries
tend
focus
risk
particular
product
design
warning
label
arguably
contributed
particular
plaintiff
injury
overall
benefits
design
label
patients
reaped
benefits
represented
slip
indeed
patients
like
respondent
ones
tort
juries
ever
see
patient
like
respondent
already
suffered
tragic
accident
phenergan
risks
longer
matter
probabilities
potentialities
contrast
fda
benefit
long
view
determinations
consider
interests
potential
users
drug
including
suffer
without
new
medical
products
juries
free
contradict
fda
expert
determinations
slip
fda
conveys
warnings
one
voice
rather
whipsawing
medical
community
potentially
conflicting
ones
today
ruling
however
parochialism
may
prevail
problem
well
illustrated
labels
borne
vesicant
drugs
many
used
chemotherapy
class
vesicants
much
dangerous
drugs
like
vast
majority
vesicant
labels
like
phenergan
either
allow
disallow
iv
push
see
appendix
infra
vesicant
extravasation
devastating
consequences
potentially
lifesaving
benefits
drugs
offer
hollow
solace
victim
tragedy
jury
analysis
particular
case
may
well
differ
fda
example
consider
mustargen
mechlorethamine
hcl
injectable
form
mustard
gas
used
anticancer
drug
mustargen
label
warns
several
places
drug
highly
toxic
indeed
drug
highly
toxic
accidental
eye
contact
occur
copious
irrigation
least
minutes
water
normal
saline
balanced
salt
ophthalmic
irrigating
solution
instituted
immediately
followed
prompt
ophthalmologic
consultation
accidental
skin
contact
occur
affected
part
must
irrigated
immediately
copious
amounts
water
least
minutes
removing
contaminated
clothing
shoes
followed
sodium
thiosulfate
solution
medical
attention
sought
immediately
contaminated
clothing
destroyed
yet
comes
administering
highly
toxic
drug
label
provides
drug
may
injected
directly
suitable
vein
injected
preferably
rubber
plastic
tubing
flowing
intravenous
infusion
set
reduces
possibility
severe
local
reactions
due
extravasation
high
concentration
drug
emphasis
added
similarly
labels
powerful
chemotherapeutic
vesicants
including
dactinomycin
oxaliplatin
vinblastine
vincristine
specifically
allow
iv
push
notwithstanding
devastating
effects
extravasated
fact
labels
drugs
allow
iv
push
striking
vesicants
much
dangerous
phenergan
also
frequently
extravasated
see
boyle
engelking
vesicant
extravasation
myths
realities
oncology
nursing
forum
arguing
rate
extravasation
considerably
higher
vesicant
administrations
regardless
fda
reasons
contraindicating
iv
push
drugs
odd
say
least
jury
vermont
order
phenergan
fda
chosen
order
mustard
sure
state
tort
suits
peacefully
coexist
fda
labeling
regime
done
decades
ante
case
far
peaceful
coexistence
fda
told
wyeth
phenergan
label
renders
use
safe
state
vermont
tort
law
said
rule
issue
squarely
therefore
reverse
judgment
vermont
appendix
opinion
alito
iv
dactinomycin
specifically
allowed
mechlorethamine
mustargen
specifically
allowed
oxaliplatin
specifically
allowed
vinblastine
specifically
allowed
vincristine
specifically
allowed
bleomycin
neither
mentioned
prohibited
carboplatin
neither
mentioned
prohibited
dacarbazine
neither
mentioned
prohibited
mitomycin
neither
mentioned
prohibited
carmustine
prohibited
iv
drip
recommended
cisplatin
prohibited
iv
drip
recommended
epirubicin
prohibited
iv
drip
recommended
etoposide
prohibited
iv
drip
recommended
ifosfamide
prohibited
iv
drip
recommended
mitoxantrone
prohibited
iv
drip
recommended
paclitaxel
prohibited
iv
drip
recommended
teniposide
prohibited
iv
drip
recommended
vinorelbine
prohibited
iv
drip
recommended
daunorubicin
prohibited
doxorubicin
prohibited
wilkes
oncology
nursing
drug
handbook
table
information
derived
dosage
administration
sections
individual
drug
labels
available
clerk
case
file
footnotes
warning
inadvertent
injection
stated
due
close
proximity
arteries
veins
areas
commonly
used
intravenous
injection
extreme
care
exercised
avoid
perivascular
extravasation
inadvertent
injection
reports
compatible
inadvertent
injection
phenergan
injection
usually
conjunction
drugs
intended
intravenous
use
suggest
pain
severe
chemical
irritation
severe
spasm
distal
vessels
resultant
gangrene
requiring
amputation
likely
circumstances
intravenous
injection
intended
cases
reported
perivascular
extravasation
arterial
placement
needle
suspect
proven
successful
management
condition
occurs
aspiration
dark
blood
preclude
needle
placement
blood
discolored
upon
contact
phenergan
injection
use
syringes
rigid
plungers
small
bore
needles
might
obscure
typical
arterial
backflow
relied
upon
alone
used
intravenously
phenergan
injection
given
concentration
greater
mg
per
ml
rate
exceed
mg
per
minute
administering
irritant
drug
intravenously
usually
preferable
inject
tubing
intravenous
infusion
set
known
functioning
satisfactorily
event
patient
complains
pain
intended
intravenous
injection
phenergan
injection
injection
stopped
immediately
provide
evaluation
possible
arterial
placement
perivascular
extravasation
app
dissent
nonetheless
suggests
physician
malpractice
exclusive
cause
levine
injury
see
post
opinion
alito
unclear
warning
helped
respondent
post
suggesting
physician
assistant
conduct
sole
cause
injury
dissent
frustration
jury
verdict
put
merits
levine
tort
claim
us
change
question
must
decide
whether
federal
law
levine
claims
wyeth
argues
presumption
apply
case
federal
government
regulated
drug
labeling
century
argument
misunderstands
principle
rely
presumption
respect
independent
sovereigns
federal
system
leads
us
assume
congress
cavalierly
causes
action
medtronic
lohr
presumption
thus
accounts
historic
presence
state
law
rely
absence
federal
regulation
part
dissent
argues
presumption
apply
claims
implied
conflict
post
long
held
contrary
see
california
arc
america
hillsborough
county
automated
medical
laboratories
see
also
rush
prudential
hmo
moran
dissent
reliance
buckman
plaintiffs
legal
see
post
especially
curious
case
involved
claims
distinguished
state
regulation
health
safety
matters
presumption
apply
see
levine
also
introduced
evidence
pfizer
withdrawn
vistaril
another
antinausea
drug
intravenous
use
several
decades
earlier
intravenous
injection
resulted
gangrene
amputations
see
app
record
event
support
argument
wyeth
propose
different
language
phenergan
warning
injection
adapted
revisions
fda
proposed
see
app
fda
approved
wyeth
application
instructed
wyeth
retain
wording
current
label
trial
proceedings
levine
indicated
language
proposed
strongly
warned
administration
trial
vermont
found
warning
differ
material
respect
warning
see
simply
stated
proposed
warning
different
stronger
also
longer
prominent
original
warning
app
indeed
concedes
fda
regard
proposed
warning
substantively
different
appears
fda
viewed
change
rejected
formatting
reasons
brief
amicus
curiae
see
also
dissent
suggestion
fda
intended
prohibit
wyeth
strengthening
warning
fairly
reflect
record
dissent
creatively
paraphrases
fda
orders
instance
conflating
warnings
administration
injection
see
post
suggest
greater
agency
attention
question
undertakes
study
phenergan
labeling
elaborate
fda
order
even
dissent
account
support
conclusion
fda
prohibited
wyeth
adding
stronger
warning
pursuant
cbe
regulation
although
first
version
bill
became
fdca
provided
federal
cause
action
damages
injured
consumers
see
introduced
witnesses
testified
right
action
unnecessary
claims
already
available
state
law
see
hearings
subcommittee
senate
committee
commerce
statement
hines
see
statement
ladds
act
attempt
modify
restate
common
law
respect
personal
injuries
congress
certain
state
requirements
concerning
medications
cosmetics
expressly
preserved
product
liability
actions
see
nothing
section
shall
construed
modify
otherwise
affect
action
liability
person
product
liability
law
state
similar
examples
see
ed
authorizing
federal
communications
commission
state
statute
regulation
legal
requirement
may
prohibit
effect
prohibiting
ability
entity
provide
interstate
intrastate
telecommunications
service
ed
statute
conflicts
purposes
requirements
chapter
permitting
secretary
interior
set
forth
state
law
regulation
preempted
superseded
ed
supp
authorizing
secretary
transportation
decide
whether
state
local
statute
conflicts
regulation
hazardous
waste
transportation
see
also
fed
reg
intent
fda
influence
civil
tort
liability
manufacturer
fed
reg
roduct
liability
plays
important
role
consumer
protection
porter
lohr
decision
fda
perspective
position
food
drug
former
chief
counsel
fda
stating
fda
regarded
state
law
complementing
agency
mission
consumer
protection
year
agency
approved
wyeth
phenergan
application
fda
advisory
committee
issued
report
finding
conclusively
budget
staff
food
drug
administration
inadequate
permit
discharge
existing
responsibilities
protection
american
public
citizens
advisory
committee
fda
report
secretary
health
education
welfare
doc
three
recent
studies
reached
similar
conclusions
see
fda
science
board
report
subcommittee
science
technology
fda
science
mission
risk
online
http
ence
internet
materials
visited
available
clerk
case
file
agency
suffers
serious
scientific
deficiencies
positioned
meet
current
emerging
regulatory
responsibilities
national
academies
institute
medicine
future
drug
safety
promoting
protecting
health
public
fda
lacks
resources
needed
accomplish
large
complex
mission
widespread
agreement
resources
postmarketing
drug
safety
work
especially
inadequate
resource
limitations
hobbled
agency
ability
improve
expand
essential
component
mission
gao
drug
safety
improvement
needed
fda
postmarket
oversight
process
http
fda
lacks
clear
effective
process
making
decisions
providing
management
oversight
postmarket
safety
issues
see
also
house
committee
oversight
government
reform
majority
staff
report
fda
career
staff
objected
agency
preemption
policies
office
chief
counsel
ignored
warnings
fda
scientists
career
officials
preemption
language
preamble
based
erroneous
assertions
ability
drug
approval
process
ensure
accurate
drug
labels
see
generally
brief
former
fda
commissioners
drs
donald
kennedy
david
kessler
amici
curiae
see
also
kessler
vladeck
critical
examination
fda
efforts
preempt
claims
geo
bates
dow
agrosciences
llc
noting
state
tort
suits
serve
catalyst
aiding
exposure
new
dangers
prompting
manufacturer
federal
agency
decide
revised
label
required
amicus
brief
similarly
undeserving
deference
unlike
government
brief
geier
american
honda
motor
explained
effects
state
law
dot
regulation
manner
consistent
agency
prior
accounts
see
government
explanation
federal
drug
regulation
departs
markedly
fda
understanding
times
relevant
case
wyeth
specific
contention
case
resembles
geier
fda
determined
additional
warning
administration
needed
thereby
setting
ceiling
phenergan
label
belied
record
discussed
fda
consider
reject
stronger
warning
injection
phenergan
see
also
app
tort
case
unlikely
obstruct
regulatory
process
record
shows
fda
paid
little
attention
issues
raised
parties
trial
footnotes
structural
limitation
may
implicated
case
federal
law
issue
beyond
scope
congress
enumerated
powers
expansion
congressional
power
increasingly
generous
interpretation
commerce
power
congress
example
creates
real
risk
congress
gradually
erase
diffusion
power
state
nation
framers
based
faith
efficiency
vitality
republic
garcia
san
antonio
metropolitan
transit
authority
dissenting
see
also
marbury
madison
cranch
powers
legislature
defined
limited
limits
may
mistaken
forgotten
constitution
written
majority
analysis
relies
part
presumption
ante
opinion
stevens
evident
text
relevant
federal
statutes
regulations
judgment
necessary
decide
whether
extent
presumption
apply
case
one
congress
enacted
clause
cf
altria
group
good
thomas
dissenting
rejecting
use
presumption
express
cases
according
pennsylvania
act
required
every
alien
years
certain
exceptions
register
year
provide
information
required
statute
plus
information
details
department
labor
industry
may
direct
pay
annual
registration
fee
receive
alien
identification
card
carry
times
show
card
whenever
may
demanded
police
officer
agent
department
labor
industry
exhibit
card
condition
precedent
registering
motor
vehicle
name
obtaining
license
operate
one
nonexempt
aliens
fail
register
subject
fine
imprisonment
failure
carry
identification
card
failure
show
upon
proper
demand
punishment
fine
imprisonment
hines
omitted
explained
federal
alien
registration
act
required
single
registration
aliens
years
age
detailed
information
specified
act
plus
additional
matters
may
prescribed
commissioner
approval
attorney
general
registrants
secrecy
federal
files
requirement
aliens
carry
registration
card
exhibited
police
others
embodied
law
wilful
failure
register
made
criminal
offense
according
justice
stone
hines
majority
analysis
resembled
inquiry
whether
federal
act
field
rather
application
simple
conflict
principles
dissenting
opinion
regardless
whether
hines
involved
field
conflict
dissent
accurately
observed
assessing
boundaries
federal
law
scope
effect
look
federal
statute
rather
speculate
congress
unstated
intentions
see
also
camps
town
harrison
thomas
dissenting
noting
field
suspect
least
applied
absence
congressional
command
particular
field
safety
act
express
provision
stated
part
whenever
federal
motor
vehicle
safety
standard
established
subchapter
effect
state
shall
authority
either
establish
continue
effect
respect
motor
vehicle
item
motor
vehicle
equipment
safety
standard
applicable
aspect
performance
vehicle
item
equipment
identical
federal
standard
safety
act
also
included
saving
clause
stated
compliance
federal
motor
vehicle
safety
standard
issued
subchapter
exempt
person
liability
common
law
majority
dissent
geier
agreed
import
express
provision
saving
clause
read
together
terms
safety
act
expressly
state
actions
see
geier
stevens
dissenting
addition
impropriety
looking
beyond
plain
text
saving
clause
regulatory
history
dot
comments
administrative
litigating
position
evaluate
safety
act
effect
unclear
geier
accurately
assessed
federal
objectives
relevant
federal
law
dissent
geier
pointed
purpose
safety
act
stated
congress
generally
reduce
traffic
accidents
deaths
injuries
persons
resulting
traffic
accidents
opinion
stevens
quoting
face
goal
course
consistent
judgment
particular
vehicle
needed
passive
restraint
system
better
protect
persons
death
injury
traffic
accidents
furthermore
dissent
observed
definition
standards
established
safety
act
impose
minimum
rather
fixed
maximum
requirements
citing
thus
dissent
view
requirements
dot
regulation
ceilings
obvious
secretary
favored
rapid
increase
required
regulations
goal
also
consistent
judgment
finding
manufacturer
acted
negligently
failed
include
airbag
particular
car
see
footnotes
indeed
respondent
conceded
wyeth
propose
adequate
warning
phenergan
risks
see
plaintiff
diana
levine
memorandum
opposition
wyeth
motion
summary
judgment
levine
american
home
products
wyeth
wncv
super
washington
specifically
respondent
noted
wyeth
proposed
language
prevented
accident
requiring
running
iv
explaining
running
iv
address
reduce
risk
injection
ibid
see
also
although
strong
enough
improved
labeling
instruction
followed
prevented
inadvertent
administration
phenergan
artery
fda
rejected
wyeth
proposal
see
app
moreover
trial
judge
final
charge
told
jury
critical
factual
issue
must
decide
whether
phenergan
label
reflects
proper
balance
risks
benefits
intravenous
administration
potential
injury
patients
see
also
recognizing
respondent
argument
phenergan
label
allowed
iv
push
means
administration
respondent
sued
physician
physician
assistant
hospital
malpractice
parties
settled
suit
undisclosed
sum
respondent
physician
sent
letter
admitted
responsibility
injury
expressed
profoun
regre
remors
actions
tr
mar
testimony
john
matthew
see
also
app
testimony
physician
assistant
jessica
fisch
noting
sense
grief
great
gladly
cut
arm
given
respondent
thereafter
physician
physician
assistant
agreed
testify
respondent
behalf
suit
wyeth
sure
congress
recognized
principles
conflict
fdca
see
drug
amendments
stat
nothing
amendments
made
act
federal
food
drug
cosmetic
act
shall
construed
invalidating
provision
state
law
unless
direct
positive
conflict
amendments
provision
state
law
provision
simply
recognizes
background
principles
conflict
traditional
saving
clause
even
displace
analysis
see
geier
american
honda
motor
saving
clause
bar
ordinary
working
conflict
principles
refused
read
general
provisions
tolerate
actual
conflict
cases
involving
impossibility
cases
emphasis
deleted
citation
omitted
fda
cited
numerous
articles
generally
discuss
costs
benefits
associated
iv
push
see
nahrwold
phelps
inadvertent
injection
mephenteramine
rocky
mountain
medical
cited
app
albo
cheung
ruth
snyder
beemtsma
effect
injections
barbituates
surgery
cited
app
corser
masey
jacob
kernoff
browne
ischaemia
following
injection
methylphenidate
diamorphine
anesthesiology
cited
app
correspondence
regarding
thiopental
thiamylal
letters
anesthesiology
cited
app
miller
arthur
stratigos
injection
barbituate
anesthesia
progress
cited
app
see
webb
lampert
accidental
arterial
injections
obstetrics
gynecology
cited
app
see
hager
wilson
gangrene
hand
following
injection
archives
surgery
cited
app
enloe
sylvester
morris
hazards
injection
hydroxyzine
canadian
anaesthetists
society
hereinafter
enloe
noting
recent
reports
occurrence
severe
necrosis
gangrene
following
administration
promethazine
cited
app
see
also
mostafavi
samimi
accidental
injection
promethazine
hcl
general
anesthesia
anesthesiology
reporting
case
gangrene
required
partial
amputation
three
fingers
phenergan
inadvertently
pushed
artery
antecubital
area
promethazine
clinical
pharmacology
gold
standard
multimedia
version
noting
nadvertent
injection
phenergan
result
arteriospasm
development
gangrene
hager
wilson
noted
common
reactions
injections
drugs
like
phenergan
include
mmediate
severe
burning
pain
well
blanching
archives
surgery
fda
required
wyeth
include
hager
wilson
observations
phenergan
label
see
app
requiring
label
warn
first
sign
injection
may
patient
reaction
sensation
fiery
pain
see
enloe
discussing
hydroxyzine
antihistamine
chemical
properties
similar
phenergan
suggesting
temporary
benefits
never
outweigh
risks
injection
see
also
goldsmith
trieger
accidental
injection
medical
emergency
anesthesia
progress
noting
risks
administration
hydroxyzine
cited
app
klatte
brooks
rhamy
toxicity
barbituates
tranquilizing
drugs
radiology
cited
app
full
knowledge
risks
fda
retained
iv
push
phenergan
although
agency
required
wyeth
incorporate
observations
enloe
article
phenergan
label
compare
enloe
arguing
every
precaution
taken
avoid
inadvertent
injection
including
use
obviously
venoclysis
app
fda
changes
phenergan
label
contrast
time
around
fda
prohibited
intravenous
use
hydroxyzine
see
testimony
harold
green
fda
decision
regulate
two
drugs
differently
notwithstanding
agency
knowledge
risks
associated
drugs
agency
recognition
relevance
articles
case
reports
regulation
phenergan
demonstrates
fda
intentionally
preserved
administration
phenergan
see
also
haas
correspondence
anesthesia
progress
hydroxyzine
restriction
lie
medicine
practice
malpractice
intravenous
techniques
unfortunately
practitioner
knows
treat
injection
technique
problems
usually
practitioner
intravenous
technique
problems
see
also
engler
freeman
kanavage
ogden
moretz
production
gangrenous
extremities
injections
surgeon
accidental
arterial
injection
often
occurs
antecubital
region
favorite
site
venopuncture
area
ulnar
brachial
arteries
superficial
easily
entered
cited
app
engler
gangrenous
extremities
resulting
injections
archives
surgery
similar
cited
app
lynas
bisset
thiopentone
anaesthesia
anesthesiologists
agree
injections
medial
aspect
antecubital
fossa
best
avoided
cited
app
waters
thiopentone
anesthesia
risk
producing
gangrene
forearm
accidental
injection
sodium
thiopentone
artery
elbow
recognised
many
years
cited
app
see
also
hager
wilson
archives
surgery
emphasizing
one
best
ways
prevent
inadvertent
injections
aware
aberrant
superficial
arteries
antecubital
forearm
wrist
hand
level
mostafavi
samimi
supra
warning
antecubital
injections
see
app
requiring
phenergan
label
warn
practitioners
eware
close
proximity
arteries
veins
commonly
used
injection
sites
consider
possibility
aberrant
aspiration
refers
drawing
small
amount
blood
back
needle
determine
whether
needle
artery
vein
ordinarily
arterial
blood
brighter
venous
blood
contact
phenergan
causes
discoloration
makes
aspiration
unreliable
method
protecting
injection
see
therefore
label
warned
using
iv
push
medical
professional
beware
spiration
dark
blood
preclude
needle
placement
blood
discolored
upon
contact
phenergan
injection
addition
respondent
medical
expert
testified
trial
principle
basic
anatomy
antecubital
fossa
contains
aberrant
arteries
see
tr
mar
testimony
daniel
see
also
ibid
noting
gray
anatomy
bible
anatomy
also
warns
arteries
antecubital
space
thus
true
long
applied
presumption
conflict
cases
ante
majority
opinion
long
ago
gibbons
ogden
wheat
inquired
whether
state
law
interfer
ed
contrary
collision
federal
law
without
ever
invoking
presumption
see
also
davis
unmasking
presumption
favor
preemption
rev
noting
many
early
cases
resulted
almost
automatic
preemption
concurrent
state
regulation
subsequent
years
sometimes
acknowledged
limited
presumption
nonetheless
remained
open
question
today
whether
presumption
applied
conflict
cases
see
crosby
national
foreign
trade
council
leave
another
day
consideration
context
presumption
preemption
moreover
never
held
presumption
applies
area
drug
labeling
long
reserved
federal
regulation
locke
see
also
buckman
plaintiffs
legal
vesicants
may
cause
blistering
severe
tissue
injury
tissue
necrosis
upon
extravasation
even
drug
injected
artery
see
schulmeister
administering
vesicants
clinical
oncology
nursing
see
also
ante
majority
opinion
noting
phenergan
labeled
irritant
cf
brief
anju
budhwani
et
al
amici
curiae
suggesting
phenergan
considered
vesicant
fda
oncology
tools
product
label
details
online
http
visited
mar
available
clerk
case
file
ibid
true
fda
regulation
hydroxyzine
see
supra
